High-income countries play a key role in the global response to Omicron. Their decisions can help increase global vaccination coverage, curb the spread of current variants, and prevent the emergence of new ones. Here we outline three actions high-income countries should take to help end the pandemic sooner.
CGD Policy Blogs
CGD co-hosted an online event in November with the U4 Anti-Corruption Resource Centre to discuss the progress and challenges in pursuit of a transparent and equitable roll out of COVID-19 vaccine. Following on earlier calls for transparency, this event built on new research from U4 and pointed to two main areas of progress as well as two priorities going forward.
African Countries Will Continue to Face Tough Choices on COVID-19 Vaccines: We’ve Developed a Toolkit That Can Help
African countries will continue to face tough choices on COVID-19 vaccines—we’ve developed a Toolkit that can help.
We conducted a joint review of the portfolio management activities of the committee overseeing COVAX R&D and manufacturing investments, known as RDMIC (R&D and Manufacturing Investment Committee). Our aim was to assess learnings from investments to date and suggest ways to strengthen future global health security preparedness and prevent the inequities observed in the COVID-19 response from repeating.
Poor understanding about vaccine capacity was one of the reasons why the world did not have the infrastructure needed to manufacture sufficient doses. This blogs proposes three actions to start tracking manufacturing capacity better and create robust estimates for the world’s vaccine manufacturing capacity.
Before Recommending the RTS,S Malaria Vaccine for Wider Use, WHO Should Address Three Key Considerations
Last month, the world woke up to promising news on malaria prevention: administering an existing malaria vaccine (RTS,S) in addition to antimalarial drugs before the rainy season reduced child hospitalizations and deaths by approximately 70 percent in Burkina Faso and Mali. These results arrived ahead of a forthcoming decision from the World Health Organization on whether to recommend RTS,S for broader use. This blog argues that WHO should consider value for money and address three key considerations before making their reccomendation.
LAC Countries are Struggling to Deliver COVID-19 Vaccinations—Six Actions Are Needed to Turn the Tide
Historically, the Americas have been the world leader in routine vaccination, vaccine introduction, and implementation of mass vaccination campaigns against infectious diseases. It was the first region to eliminate rubella and measles, eradicate smallpox, and be declared polio-free.
Vaccines have become a central instrument of our long-term response to the pandemic. Vaccination campaigns have now started around the world and will confer significant direct protection against infection, severe illness, and death to those inoculated. It may also protect against transmission, though robust evidence is yet to be confirmed.
Effective vaccines are developed through collaboration between governments, publicly funded research universities and for-profit pharmaceutical companies. But the incentives to produce the doses can often leave out lower-income countries.
Five key operational levers and choices determine how fast countries are able to roll out the COVID-19 vaccine. Ideally, someone at the national level makes these decisions, but this hasn’t always been easy in multi-level government systems.